e8vk
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) July 25, 2007
Pharmion Corporation
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
| Delaware
|
|
000-50447
|
|
84-1521333 |
|
|
|
|
|
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File
Number)
|
|
(IRS Employer
Identification No.) |
| |
|
|
| 2525 28th Street, Boulder, Colorado
|
|
80301 |
|
|
|
|
| (Address of principal executive offices)
|
|
(Zip Code) |
Registrant’s telephone number, including area code 720-564-9100
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
|
|
|
| o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
| o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
| o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
| o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
|
|
|
| Item |
|
2.02 Results of Operations and Financial Condition |
On July 25, 2007, Pharmion Corporation issued a press release
describing the financial results of the Company for the quarter
ended June 30, 2007. A copy of the press release is attached as
Exhibit 99.1 and is being incorporated herein by reference.
The information incorporated by reference in Item 2.02 of this Form
8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for
purposes of Section 18 of the Securities Exchange Act of 1934 (the
“Exchange Act”) or otherwise subject to the liabilities of that
section, nor shall it be deemed incorporated by reference in any
filing under the Securities Act of 1933 or the Exchange Act,
regardless of any general incorporation language in such filing.
|
|
|
| Item |
|
9.01 Financial Statements and Exhibits. |
(d) Exhibits
| |
|
|
| Exhibit |
|
|
| Number |
|
Description |
|
|
|
99.1
|
|
Press Release, dated July 25, 2007. |
|
|
This exhibit is furnished pursuant to Item 2.02 and shall not be deemed to be “filed.” |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
| |
|
|
|
|
| |
PHARMION CORPORATION
|
|
| Date: July 25, 2007 |
By: |
/s/ Erle T. Mast
|
|
| |
|
Name: |
Erle T. Mast |
|
| |
|
Title: |
Chief Financial Officer |
|
| |
EXHIBIT INDEX
| |
|
|
| Exhibit |
|
|
| Number |
|
Description |
|
|
|
99.1
|
|
Press Release, dated July 25, 2007. |
|
|
This exhibit is furnished pursuant to Item 2.02 and shall not be deemed to be “filed.” |